Literature DB >> 18306530

Pathology and pathogenesis of rheumatic heart disease.

P Chopra1, Hanni Gulwani.   

Abstract

Cardiovascular disease is on the rise. In India and other developing countries, rheumatic heart disease (RHD) continues to be a major public health problem and contributes to significant cardiac morbidity and mortality. RHD in the juvenile age group namely juvenile mitral stenosis is a variant which is unique to the Indian subcontinent. Severe valve deformities lead to high morbidity and mortality. Despite various measures no appreciable decline in prevalence of RHD has been documented. At autopsy, mitral valve was most commonly affected either alone or in combination with aortic and tricuspid valves. Both functional and organic involvement of tricuspid valve was documented. It has been convincingly demonstrated that molecular mimicry between Streptococcus pyogenes antigen and human proteins lead to autoimmune reactions both humoral and cell mediated causing RF/RHD. Heart tissues namely the valves, left atrial appendage (LAA) and myocardium reveal variable amounts of infiltration by lymphocytes. Significant endocarditis and valvulitis is observed in these cases. CD4+ T cells are most likely the ultimate effectors of chronic valve lesions in RHD. They can recognize Streptococcal M5 protein peptides and produce various inflammatory cytokines such as TNF-alpha, IFN-gamma, IL-10, IL-4 which could be responsible for progressive fibrotic valvular lesions. Cardiac myosin has been defined as a putative autoantigen recognized by autoantibodies of RF patients. Cross reactivity between cardiac myosin and group A beta hemolytic Streptococcal M protein has been adequately demonstrated. Cardiac myosin has been shown to produce myocarditis in rats and mice. Valvulitis/ endocarditis has been observed in excised LAA, cardiac valves and in hearts at autopsy from cases of RHD. The disease predominantly affects the valvular endocardium culminating in crippling valve deformities. Endocardial infiltrate and their migration into the valve substance has been elegantly demonstrated in rats and mice. Immune responses against cardiac myosin lead to valvular heart disease and infiltration of the heart by Streptococcal M protein reactive T lymphocytes. Mitral valves showed various degrees of calcification. An interesting observation is the nature of calcification in diseased/distorted valves in RHD. Recent studies indicate that calcification is not merely an inactive, "dystrophic" process but involves a regulated inflammatory process associated with expression of osteoblast markers and neoangiogenesis. Increased plasma osteopontin levels correlated with severity of mitral valve calcification. Further evidence of inflammation is supported by high levels of advanced oxidation protein products and high sensitive C-reactive protein in plasma detected in patients with RHD. Presence of inflammatory cells and increased expression of several cytokines in cases of "end stage" RHD reflects a possible subclinical, ongoing insult/injury to some unrecognized antigenic stimulus by beta hemolytic Streptococcal antigens that have sensitized/primed the various target tissues and which further culminate in permanent valve deformities.

Entities:  

Mesh:

Year:  2007        PMID: 18306530

Source DB:  PubMed          Journal:  Indian J Pathol Microbiol        ISSN: 0377-4929            Impact factor:   0.740


  15 in total

1.  A comparison of different antibiotic regimens for the treatment of infective endocarditis.

Authors:  Arturo J Martí-Carvajal; Mark Dayer; Lucieni O Conterno; Alejandro G Gonzalez Garay; Cristina Elena Martí-Amarista
Journal:  Cochrane Database Syst Rev       Date:  2020-05-14

2.  Myocardial extracellular volume assessed by cardiovascular magnetic resonance may predict adverse left ventricular remodeling in rheumatic heart disease after valvular surgery.

Authors:  Shuang Li; Simeng Wang; Jianqun Yu; Jiayu Sun; Wei Cheng; Jing Liu; Huaxia Pu; Yucheng Chen; Liqing Peng
Journal:  Quant Imaging Med Surg       Date:  2022-04

Review 3.  Sudden adult death.

Authors:  Neil E I Langlois
Journal:  Forensic Sci Med Pathol       Date:  2009-07-18       Impact factor: 2.007

4.  Carotid intima media thickness and arterial stiffness in children with acute rheumatic fever.

Authors:  Murat Çiftel; Osman Yılmaz; Fırat Kardelen; Abdullah Kocabaş
Journal:  Pediatr Cardiol       Date:  2013-06-15       Impact factor: 1.655

5.  "MacCallum Plaque of the Heart": A Medicolegal Case.

Authors:  Udasimath Shivakumarswamy; Sankappa P Sinhasan; R Purushotham; K R Nagesha
Journal:  Heart Views       Date:  2010-06

6.  Ubiquitin specific peptidase 4 stabilizes interferon regulatory factor protein and promotes its function to facilitate interleukin-4 expression in T helper type 2 cells.

Authors:  Zhixiang Guo; Peng Xu; Shangqing Ge; Chengxin Zhang; Xiaoyan Zheng; Jinguo Xu; Zhuang Liu; Bin Li; Shenglin Ge
Journal:  Int J Mol Med       Date:  2017-08-03       Impact factor: 4.101

7.  High sensitive C-reactive protein and interleukin 6 in atrial fibrillation with rheumatic mitral stenosis from Indian cohort.

Authors:  Gautam Sharma; Sudhir Shetkar; Ashu Bhasin; Lakshmy Ramakrishnan; Rajnish Juneja; Nitish Naik; Ambuj Roy; Sivasubramanian Ramakrishnan; Balram Bhargava; Vinay Kumar Bahl
Journal:  Indian Heart J       Date:  2016-12-20

8.  The new face of rheumatic heart disease in South West Nigeria.

Authors:  Patience Olayinka Akinwusi; Johnson Olarewaju Peter; Adebayo Tolulope Oyedeji; Abiona Oluwadamilola Odeyemi
Journal:  Int J Gen Med       Date:  2013-05-23

9.  Clinical and echocardiographic features of children with rheumatic heart disease and their serum cytokine profile.

Authors:  Sulafa Khalid Mohamed Ali; Inaam Noor Eldaim; Samia Hassan Osman; Sahar Mohamed Bakhite
Journal:  Pan Afr Med J       Date:  2012-10-19

10.  CC-chemokine receptor 7 and its ligand CCL19 promote mitral valve interstitial cell migration and repair.

Authors:  Xiaozhi Wang; Liang Wang; Liping Miao; Rong Zhao; Yanhu Wu; Xiangqing Kong
Journal:  J Biomed Res       Date:  2015-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.